Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 9/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.55 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14278777 | 0.88 | MEN1 (0.65) | MCL1MEN1KMT2AP4HTMMDM2 | |
| SCHEMBL4267162 | 0.88 | MCL1 (0.58) | MCL1MEN1KMT2AP4HTMP2RY12 | |
| SCHEMBL9658088 | 0.86 | MEN1 (0.63) | MCL1MEN1KMT2AP4HTMMDM2 | |
| SCHEMBL4271936 | 0.84 | NPC1 (0.55) | MCL1P2RY12MDM2 | |
| SCHEMBL2899930 | 0.82 | MCL1 (0.52) | MCL1 | |
| SCHEMBL25347596 | 0.81 | MCL1 (0.57) | MCL1MEN1KMT2AP4HTMMDM2 | |
| SCHEMBL10051978 | 0.81 | MCL1 (0.51) | MCL1MEN1KMT2AP2RY12XDH | |
| SCHEMBL1111239 | 0.81 | P2RY12 (0.52) | MCL1P2RY12 | |
| SCHEMBL9658085 | 0.80 | MCL1 (0.55) | MCL1MEN1KMT2AP4HTMMDM2 | |
| SCHEMBL4263343 | 0.80 | MCL1 (0.52) | MCL1MEN1KMT2AP2RY12XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012019299-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-16 | — | — | WO | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1845081-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048258-A1 | Amide Compound | DLAT, DGAT1, DGAT2 | MCL1 3227/4885MEN1 4668/4885KMT2A 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.